MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
The main purpose of this open-label, dose-escalation, phase Ib study is to identify the
appropriate dose of MEN1611 to be used in combination with Trastuzumab with/without
Fulvestrant for the treatment of advanced or metastatic HER2-positive breast cancer